Kalaris Therapeutics, Inc. Research And Development Expense

• Kalaris Therapeutics, Inc. showed a decrease of -31.7% in Research And Development Expense from 2024 to 2025.
• This data is from Kalaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Kalaris Therapeutics, Inc.'s Research And Development Expense has grown by 89.3%.
• Historical annual values: Fiscal year 2025: $30.75 million | Fiscal year 2024: $45.04 million | Fiscal year 2023: $133.07 million | Fiscal year 2022: $118.87 million | Fiscal year 2021: $120.74 million | Fiscal year 2020: $49.66 million | Fiscal year 2019: $16.25 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026